

Submission Confirmation

From: Journal of Applied Pharmaceutical Science (japs@ejmanager.com)

To: utamipurwanto@yahoo.com

Date: Thursday, May 12, 2016 at 11:36 AM GMT+7

Dear Dwi Utami Purwanto,

Your submission entitled **Formation and Characterization of Mefenamic acid-Nicotinamide Cocrystal during Co-milling Based on X-ray Powder Diffraction Analysis** (Manuscript Number: JAPS-2016-05-363) has been received by **Journal of Applied Pharmaceutical Science**.

You could follow status of your manuscript by login to your author account at www.ejmanager.com.

Thank you for submitting your work to our journal.

Best regards,

Editor
Journal of Applied Pharmaceutical Science
<http://japsonline.com/index.php>

<http://www.scopemed.org>

[Author Login Page](#)

[Reviewer Login Page](#)

[Follow scopemed/ejmanager on twitter](#)

[Index of Fulltext Journals](#)

Letter

Article Title: Formation and Characterization of Mefenamic acid-Nicotinamide Cocrystal during Co-milling Based on X-ray Powder Diffraction Analysis

Letter Subject: Article Revision Letter for Authors - (JAPS-2016-05-363)

Letter:

Dear Dwi Utami Purwanto,

Your manuscript entitled "Formation and Characterization of Mefenamic acid-Nicotinamide Cocrystal during Co-milling Based on X-ray Powder Diffraction Analysis" (Ms.Nr. JAPS-2016-05-363) was reviewed by referees. As initial decision, your manuscript was found interesting but some revisions have to be made before it can reach a publishable value.

Please answer all the comments below point-by-point in an accompanying response letter to your revised submission.

You should send your revised manuscript via our online system available at <http://my.ejmanager.com/japs/>

Please add journals@ejmanager.com in your contact list to ensure the safe delivery of our emails to your inbox.

Sincerely yours,

Editorial Office
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://japsonline.com/index.php>

COMMENTS for Authors:

The authors have done good job in explaining the process in details. however, it requires some more additional information to get more clear understanding with respect to article for a future readers.

1. Pg.2: Please correct grammar, " The MFA form I is a marketable form"
2. Methods: In DSC, please provide the rational for choosing 10⁰C as a heating rate.
3. Is it a typo? The IR absorption bands (Fig. 2) in the FTIR spectrum of MFA form I and MFA II showed characteristic differences in the region of wave number 3345 cm⁻¹ as NH stretching in MFA form I and 3306 cm⁻¹ in MFA form I.
4. What is the run time for XRPD spectra? If it is a more, than you will likely to miss some events, (such as intermediate amorphous form).
5. Did author any difference in solubility after making same cocrystals from both MFA forms?
6. Please provide DSC thermograms (parameters to measure, melting point, heat of fusion and heat capacity), and SEM images of formulated cocrystals after grinding.

Letter Sent Date: Jun 10, 2016

Dear Editor of Journal of Applied Pharmaceutical Science

Thank you very much for your letter revision of our article. We apologize for the long time to respond. We need time to complete our article to fulfill the inquiry from the reviewer.

Herewith, we give the explanation of the question from reviewer by point to point as below :

1. Pg.2: Please correct grammar, " The MFA form I is a marketable form"

Answer :

We have been corrected on page 2 of the sentence "The MFA Form I is a marketable form" to "The MFA Form I is a commercially marketable form of mefenamic acid".

2. Methods: In DSC, please provide the rational for choosing 10°C as a heating rate.

Answer :

We used the 10°C as heating rate because the melting point's range of MFA I, MFA II and nicotinamide are wide. In the other hand we did not observe the formation of co-crystals DSC based on the analysis, that required the lower heating rate.

3. Is it a typo? The IR absorption bands (Fig. 2) in the FTIR spectrum of MFA form I and MFA II showed characteristic differences in the region of wave number 3345 cm⁻¹ as NH stretching in MFA form I and 3306 cm⁻¹ in MFA form I.


Answer :

We have made corrections in the sentence "The IR absorption bands (Fig. 2) in the FTIR spectrum of MFA form I and MFA form II showed characteristic differences in the region of wave number 3345 cm⁻¹ as NH stretching in MFA form I and 3306 cm⁻¹ in MFA form I " to " The IR absorption bands (Fig. 2) in the FTIR spectrum of MFA form I and MFA form II showed characteristic differences in the region of wave number 3345 cm⁻¹ as NH stretching in MFA form II and 3306 cm⁻¹ in MFA form I "(page 6)

4. What is the run time for XRPD spectra? If it is a more, than you will likely to miss some events, (such as intermediate amorphous form).

Answer :

We have done XRD test of MFA-NIC co-milling within 2 minutes, 4 minutes and 8 minutes. Based on the diffractogram result there was no intermediate amorphous form.



5. Did author any difference in solubility after making same cocrystals from both MFA forms?

Answer :

We are not tested the solubility of co-crystals produced yet, due to the limitations of the test equipment and the required sample.

6. Please provide DSC thermograms (parameters to measure, melting point, heat of fusion and heat capacity), and SEM images of formulated cocrystals after grinding.

Answer :

We have added the DSC parameters and SEM of co-crystals in Table 2 and Figure 6.

Thank you in advance for your feedback. We hope that our revision will fulfill the reviewer inquiry.

Sincerely,

The corresponding author

Dwi Utami
School of Pharmacy, Institute Bandung of Technology
Bandung, Indonesia
Email: utamipurwantoro@yahoo.com

Article Revision Letter for Authors - (JAPS-2016-05-363)

From: Journal of Applied Pharmaceutical Science (japs@ejmanager.com)

To: utamipurwanto@yahoo.com

Date: Thursday, August 11, 2016 at 02:23 PM GMT+7

Dear Dr. Dwi Utami Purwanto,

The revisions for your manuscript titled -Formation and Characterization of Mefenamic acid-Nicotinamide Cocrystal during Co-milling Based on X-ray Powder Diffraction Analysis- and manuscript number (JAPS-2016-05-363) was reviewed by Editorial Board of Journal of Applied Pharmaceutical Science and decided that the following revisions should be done. Please answer all the comments below, in your answer letter.

You should send your revised manuscript by journal Submit Article page.

Please add journals@ejmanager.com in your contact list to ensure the safe delivery of our emails to your inbox.

Sincerely yours,

Editor
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://japsonline.com/index.php>
<http://my.ejmanager.com/japs>

COMMENTS for Authors:

Reviewer - 1 --- 2. Review

The article is suitable for publication. However, it required to add more reference from peer reviewed articles. Below are few examples you can add all below references:

For milling:

- 1) Impact of Nanosizing on Solubility and Dissolution Rate of Poorly Soluble Pharmaceuticals
- 2) Solid-state transformation of different gabapentin polymorphs upon milling and co-milling
- 3) A novel polymorph of gadolinium tetrahydroborate produced by mechanical milling
- 4) A Review: Pharmaceutical and Pharmacokinetic Aspect of Nanocrystalline Suspensions
- 5) Spectroscopic-Based Chemometric Models for Quantifying Low Levels of Solid-State Transitions in Extended Release Theophylline Formulations
- 6) Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations
- 7) Effect of Milling on Solid State Transformation of Sulfamethoxazole

<http://www.scopemed.org>
[Author Login Page](#)
[Reviewer Login Page](#)
[Follow scopemed/ejmanager on twitter](#)
[Index of Fulltext Journals](#)

Revised Article Submission

From: Journal of Applied Pharmaceutical Science (japs@ejmanager.com)

To: utamipurwanto@yahoo.com

Date: Monday, August 15, 2016 at 04:20 AM GMT+7

Aug 14, 2016

Dear Dwi Utami Purwanto,

Your REVISED ARTICLE entitled '**Formation and Characterization of Mefenamic acid-Nicotinamide Cocrystal during Co-milling Based on X-ray Powder Diffraction Analysis**' has been received by **Journal of Applied Pharmaceutical Science**.

You could follow status of your manuscript by login to your author account at www.ejmanager.com.

Thank you for submitting your REVISED version of your article.

Best regards,

Editorial Board
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://japsonline.com/index.php>
<http://my.ejmanager.com/japs>

<http://www.scopemed.org>
[Author Login Page](#)
[Reviewer Login Page](#)
[Follow scopemed/ejmanager on twitter](#)
[Index of Fulltext Journals](#)

Decision Letter to Authors - Acceptance - (JAPS-2016-05-363)

From: Journal of Applied Pharmaceutical Science (japs@ejmanager.com)

To: utamipurwantoro@yahoo.com

Date: Tuesday, August 16, 2016 at 06:03 PM GMT+7

Dear Dr. Dwi Utami,

I am pleased to inform you that your manuscript titled as "Formation and Characterization of Mefenamic acid-Nicotinamide Cocrystal during Co-milling Based on X-ray Powder Diffraction Analysis" (Manuscript Number: JAPS-2016-05-363) was accepted for publication in the Journal of Applied Pharmaceutical Science. You are required to submit article processing charges USD 75 within next three days of receiving this mail through Banking/Paypal. Payment details are as follows;

For SWIFT/wire transfer:
[Please add US \$ 10 extra for bank transaction charges]
A/C Name: OPEN SCIENCE PUBLISHERS LLP
A/C No. 50200005570011
Bank Name: HDFC bank Pvt. Ltd.
IFSC: HDFC0000192
SWIFT Code: HDFCINBBXXX
MICR code: 474240002

Paypal email: opensciencepublishersllp@gmail.com

Please send a scanned copy of the deposition receipt of amount transferred to editor@japsonline.com

You could check your possible publication date at your author page.
You may login to your author account page, and visit accepted articles section in order to get official/formal acceptance letter as PDF.

I would like to remind that you could send your future manuscripts to Journal of Applied Pharmaceutical Science.

Sincerely yours,

Paras Sharma
Associate Editor
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://japsonline.com/index.php>

<http://www.scopemed.org>
[Author Login Page](#)
[Reviewer Login Page](#)
[Follow scopemed/ejmanager on twitter](#)
[Index of Fulltext Journals](#)

Read Proof of Your Article at eJManager - (JAPS-2016-05-363)

From: Journal of Applied Pharmaceutical Science (japs@ejmanager.com)

To: utamipurwanto@yahoo.com

Date: Sunday, October 2, 2016 at 07:01 PM GMT+7

Dear Dwi Utami Purwanto,

Your article "Formation and Characterization of Mefenamic acid-Nicotinamide Cocrystal during Co-milling Based on X-ray Powder Diffraction Analysis" is almost ready for publication at Journal of Applied Pharmaceutical Science. But before publication your final check will be highly appreciated. For this reason, the galley proof of your accepted article was uploaded to your author homepage.

Please log in, download the proof and check/read it carefully for any mistake or typographical error(s); then submit your corrections (if exist) within 48 hours. Please also consider that no changes can be made in your article after this step.

Please read the guidelines given below for submission of corrections for galley proof (if any).

Editor

Journal of Applied Pharmaceutical Science

editor@japsonline.com

<http://japsonline.com/index.php>

<http://my.ejmanager.com/japs>

Guidelines for sending the corrections for galley proof;

1. Write page number, Major/minor heading and line number.
2. Write the uncorrected text, corrections required and corrected text.
3. Do not send unnecessary corrections.

For example;

Correction: 1

Page no 1

Major heading: Material and Methods

Minor Heading: Plant material

Line no: 4

Uncorrected text: □□..leaves of the plant was collected□□

Corrected text: □□..leaves of the plant were collected□□

Correction: 2

Page no 1

Line no: 4

Major heading: Material and Methods

Minor Heading: Animal

Uncorrected text: □□..Animals were keep at□□

Corrected text: □□..Animals were kept at □□

[Link: <http://my.ejmanager.com/japs/>]

<http://www.scopemed.org>

[Author Login Page](#)

[Reviewer Login Page](#)

[Follow scopemed/ejmanager on twitter](#)

[Index of Fulltext Journals](#)

Fw: Submit article processing charge

From: Dwi Utami (utamipurwantoro@yahoo.com)

To: teguh.purwantoro@pertamina.com

Date: Friday, August 19, 2016 at 03:03 AM GMT+7

From: Editor JAPS <editor@japsonline.com>
Sent: Kamis, 18 Agustus 2016 22.30
To: Dwi Utami
Subject: Re: Submit article processing charge

Dear Author

Please find the full address:

Open Science Publishers LLP
Gulmohar, Siroal Road, City- Gwalior-474001, India.

Thanks & Regards

Editorial Office
Journal of Applied Pharmaceutical Science
www.japsonline.com
editor@japsonline.com
+91-8871343380

On Thu, Aug 18, 2016 at 9:33 AM, Dwi Utami <utamipurwantoro@yahoo.com> wrote:

Dear Paras Sharma,
Associate Editor Journal of Applied Pharmaceutical Science

I am very glad to received your email about acceptance decision letter of my article (Manuscript Number : JAPS-2016-05-363). This day I would like to follow the payment procedure to Open Science Publisher.

Due to fulfill the banking transfer requirement, I need some information about ***The City and The country of Open Science Publisher***. I am really pleasure if I can get this information in the short time.

Thank you very much of your respons.

Best regards,

Dwi Utami Purwantoro
Institute of Bandung Technology
Indonesia